Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells

Oncogene

Volumn 25, Issue 45, 2006, Pages 6113-6122

  Patterson, S G ^a,b   Wei, S ^a,c   Chen, X ^a,c   Sallman, D A ^a,c   Gilvary, D L ^a,c   Zhong, B ^a,c   Pow Sang, J ^a,b   Yeatman, T ^a   Djeu, J Y ^a,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b Genitourinary Oncology Program   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Chemoresistance; Clusterin; Prostate cancer; siRNA; Stat1

Indexed keywords

CLUSTERIN; DOCETAXEL; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT3 PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIZATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENOMICS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE SEQUENCE; CELL LINE; CLUSTERIN; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; RNA, SMALL INTERFERING; STAT1 TRANSCRIPTION FACTOR; TAXOIDS;

EID: 33749825228     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209632     Document Type: Article

References (48)

1. Assikis VJ, Do KA, Wen S, Wang X, Cho-Vega JH, Brisbay S et al. (2004). Clin Cancer Res 10: 6770-6778.
2. Barton BE, Murphy TF, Shu P, Huang HF, Meyenhofer M, Barton A. (2004). Mol Cancer Ther 3: 1183-1191.
3. Bettuzzi S, Davalli P, Astancolle S, Carani C, Madeo B, Tampieri A et al. (2000). Cancer Res 60: 28-34.
4. Cochet O, Frelin C, Peyron JF, Imbert V. (2006). Cell Signal 18: 449-455.
5. Culine S, Droz JP. (2000). Ann Oncol 11: 1523-1530.
6. Darnell Jr JE. (1997). Science 277: 1630-1635.
7. Debatin KM, Poncet D, Kroemer G. (2002). Oncogene 21: 8786-8803.
8. De Marzo AM, DeWeese TL, Platz EA, Meeker AK, Nakayama M, Epstein JI et al. (2004). J Cell Biochem 91: 459-477.
9. DeMiguel F, Lee SO, Lou W, Xiao X, Pflug BR, Nelson JB et al. (2002). Prostate 52: 123-129.
10. Dhir R, Ni Z, Lou W, DeMiguel F, Grandis JR, Gao AC. (2002). Prostate 51: 241-246.
11. El-Hashemite N, Zhang H, Walker V, Hoffmeister KM, Kwiatkowski DJ. (2004). Cancer Res 64: 3436-3443.
12. Geney R, Ungureanu M, Ojima I. (2002). Clin Chem Lab Med 40: 918-925.
13. Hengartner MO. (2000). Nature 407: 770-776.
14. Herr I, Debatin KM. (2001). Blood 98: 2603-2614.
15. Ho SM, Leav I, Ghatak S, Merk F, Jagannathan VS, Mallery K. (1998). Am J Pathol 153: 131-139.
16. Horvath CM. (2000). Trends Biochem Sci 25: 496-502.
17. Humphreys DT, Carver JA, Easterbrook-Smith SB, Wilson MR. (1999). J Biol Chem 274: 6875-6881.
18. Johnstone RW, Ruefli AA, Lowe SW. (2002). Cell 108: 153-164.
19. July LV, Beraldi E, So A, Fazli L, Evans K, English JC et al. (2004). Mol Cancer Ther 3: 223-232.
20. Lacroix H, Ligeza C. (1998). Expert Opin Investig Drugs 7: 273-281.
21. Lee SO, Lou W, Johnson CS, Trump DL, Gao AC. (2004). Prostate 60: 178-186.
22. Legrand A, Vadrot N, Lardeux B, Bringuier AF, Guillot R, Feldmann G. (2004). Liver Int 24: 149-160.
23. Liu K, Caldwell SA, Abrams SI. (2005). Cancer Res 65: 1045-1054.
24. Lowe SW, Lin AW. (2000). Carcinogenesis 21: 485-495.
25. Kominsky SL, Hobeika AC, Lake FA, Torres BA, Johnson HM. (2000). Cancer Res 60: 3904-3908.
26. Makarovskiy AN, Siryaporn E, Hixson DC, Akerley W. (2002). Cell Mol Life Sci 59: 1198-1211.
27. Milbank AJ, Dreicer R, Klein EA. (2002). Urology 60: 738-741.
28. Miller ML, Ojima I. (2001). Chem Rec 1: 195-211.
29. Miyake H, Chi KN, Gleave ME. (2000a). Clin Cancer Res 6: 1655-1663.
30. Miyake H, Hara I, Kamidono S, Gleave ME, Eto H. (2003). Oncol Rep 10: 469-473.
31. Miyake H, Nelson C, Rennie PS, Gleave ME. (2000b). Cancer Res 60: 170-176.
32. Miyake H, Pollak M, Gleave ME. (2000c). Cancer Res 60: 3058-3064.
33. Nelson WG, De Marzo AM, Isaacs WB. (2003). N Engl J Med 349: 366-381.
34. Nickerson T, Miyake H, Gleave ME, Pollak M. (1999). Cancer Res 59: 3392-3395.
35. O'Sullivan J, Whyte L, Drake J, Tenniswood M. (2003). Cell Death Differ 10: 914-927.
36. Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC. (2001). Carcinogenesis 22: 965-973.
37. Peto J. (2001). Nature 411: 390-395.
38. Petrylak DP. (2005). Urology 65: 3-7.
39. Petrylak DP, Tangen CM, Hussain MH, Lara Jr PN, Jones JA, Taplin ME et al. (2004). N Engl J Med 351: 1513-1520.
40. Pucci S, Bonanno E, Pichiorri F, Angeloni C, Spagnoli LG. (2004). Oncogene 23: 2298-2304.
41. Stephanou A, Latchman DS. (2003). Int J Exp Pathol 84: 239-244.
42. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. (2004). N Engl J Med 351: 1502-1512.
43. Thomas M, Finnegan CE, Rogers KM, Purcell JW, Trimble A, Johnston PG et al. (2004). Cancer Res 64: 8357-8364.
44. Trougakos IP, Gonos ES. (2002). Int J Biochem Cell Biol 34: 1430-1448.
45. Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES. (2004). Cancer Res 64: 1834-1842.
46. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S et al. (2004). Nat Med 10: 48-54.
47. Zellweger T, Kiyama S, Chi K, Miyake H, Adomat H, Skov K et al. (2003). BJU Int 92: 463-469.
48. Zellweger T, Miyake H, Cooper S, Chi K, Conklin BS, Monia BP et al. (2001). J Pharmacol Exp Ther 298: 934-940.